Alleviant Medical Announces Presentation of Clinical Data at American College of Cardiology and EuroPCR Conferences
Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved ejection fraction (HFpEF). Read More →
Alleviant Medical Receives Breakthrough Device Designation From FDA for Transcatheter Technology
The technology offers a no-implant interatrial shunt therapy for patients suffering from heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) who remain symptomatic despite optimal guideline directed medical therapy. Read More →
Alleviant Medical completes $6.5m offering
Congestive heart failure treatment developer Alleviant Medical filed an SEC Form D to confirm the sale of $6.5 million in an equity offering. The Austin, Texas-based company reached its total offering amount of $6.5 million after making the first sale in the new notice on May 1. It had no intention of letting the offering last longer than one year and did not make it in connection with a business transaction.
Read More →
Congestive heart failure device dev Alleviant Medical raises $1m
Alleviant Medical has raised $1.1 million in a new round of debt and options financing, according to an SEC filing posted this week. Money in the round came from 15 unnamed sources, according to the SEC filing, with the first sale recorded on December 19 last year.
Texas Medical Center Announces $25 Million TMC Venture Fund
The Texas Medical Center, the largest medical complex in the world, today announced the TMC Venture Fund, a $25 million initiative designed to support technologies and early-stage companies to flourish in Houston’s health care ecosystem and further the TMC’s mission to advance health, education and research.